Drug class in one race
PI3K-alpha drugs for HR+/HER2- Metastatic Breast Cancer
2 tracked PI3K-alpha drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the PI3K-alpha page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
2 approved / phase 4
Head-to-head evidence: Alpelisib (BYL719) vs Inavolisib